EDP Sciences logo
Subscriber Authentication Point
Search
Menu
Home All issues Volume 25 / No 12 (Décembre 2009) Med Sci (Paris), 25 12 (2009) 1046-1052 References
Free Access
Issue
Med Sci (Paris)
Volume 25, Number 12, Décembre 2009
Anticorps monoclonaux en thérapeutique
Page(s) 1046 - 1052
Section I - De la conception à la production
DOI https://doi.org/10.1051/medsci/200925121046
Published online 15 December 2009
  1. Schrama D, Reisfeld RA, Becker JC. Antibody targeted drugs as cancer therapeutics. Nat Rev Drug Discovery 2006; 5 : 147–59. [Google Scholar]
  2. Wu AM, Senter PD. Arming antibodies : prospects and challenges for immunoconjugates. Nat Biotech 2005; 23 : 1137–46. [Google Scholar]
  3. Tolcher AW, Sugarman S, Gelmon KA, et al. Randomized phase II study of BR96-doxorubicin conjugate in patients with metastatic breast cancer. J Clin Oncol 1999; 17 : 478–84. [Google Scholar]
  4. Lambert JM. Drug-conjugated monoclonal antibodies for the treatment of cancer. Curr Opin Pharm 2005; 5 : 543–9. [Google Scholar]
  5. Chari RVJ. Targeted cancer therapy : conferring specificity to cytotoxic drugs. Acc Chem Res 2008; 41 : 98–107. [Google Scholar]
  6. Amadori S, Stasi R. Integration of monoclonal antibodies and immunoconjugates into the treatment of acute myeloid leukaemia. Curr Opin Hematol 2008; 15 : 95–100. [Google Scholar]
  7. Stasi R. Gemtuzumab ozogamicin : an anti-CD33 immunoconjugate for the treatment of acute myeloid leukaemia. Expert Opin Biol Ther 2008; 8 : 527–40. [Google Scholar]
  8. Walters RB, Gooley TA, Van Der Velden VH, et al. CD33 expression and P-glycoprotein-mediated drug efflux inversely correlate and predict clinical outcome in patients with acute myeloid leukaemia treated with gemtuzumab ozogamicin monotherapy. Blood 2007; 109 : 4168–70. [Google Scholar]
  9. Di Joseph JF, Armellino DC, Boghaert ER, et al. Antibody-targeted chemotherapy with CMC-544 : a CD22-targeted immunoconjugate of calicheamicin for the treatment of B-lymphoid malignancies. Blood 2004; 103 : 1807–14. [Google Scholar]
  10. Chan SY, Gordon AN, Coleman RE, et al. A phase 2 study of the cytotoxic immunoconjugate CMB-401 (hctM01-calicheamicin) in patient with platinum-sensitive recurrent epithelial ovarian carcinoma. Cancer Immunol Immunother 2003; 52 : 243–8. [Google Scholar]
  11. Lewis Phillips GD, Li G, Dugger DL, et al. Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjuguate. Cancer Res 2008; 68 : 9280–90. [Google Scholar]
  12. Erickson HK, Park PU, Widdison WC, et al. Antibody-maytansinoid conjugates are activated in targeted cancer cells by lysosomal degradation and linker-dependent intracellular processing.Cancer Res 2006; 66 : 4426–33 [Google Scholar]
  13. Sanderson RJ, Hering MA, James SF, et al. In vivo drug-linker stability of an anti-CD30 dipeptide-linked auristatin immunoconjugate. Clin Cancer Res 2005; 11 : 843–52. [Google Scholar]
  14. Tse KF, Jeffers M, Pollack VA, et al. CR011, a fully human monoclonal antibody-auristatin E conjugate, for the treatment of melanoma. Clin Cancer Res 2006; 12 : 1373–82. [Google Scholar]
  15. Kovtun YV, Goldmacher VS. Cell killing by antibody-drug conjugates.Cancer Lett 2007; 255 : 232–40. [Google Scholar]
  16. Polson AG, Calemine-Fenaux J, Chan P, et al. Antibody-drug conjugates for the treatment of non-Hodgkin’s lymphoma : target and linker-drug selection. Cancer Res 2009; 69 : 2358–64. [Google Scholar]
  17. Law CH, Cerveny CG, Gordon KA, et al. Efficient elimination of B-lineage lymphomas by anti-CD20-auristatin conjugates. Clin Cancer Res 2004; 10 : 7842–51. [Google Scholar]
  18. Ingle GS, Chan P, Elliott JM, et al. High CD21 expression inhibits internalization of anti-CD19 antibodies and cytotoxicity of antiCD19-drug conjugate. Br J Haematol 2007; 140 : 46–58. [Google Scholar]
  19. Kovtun YV, Audette CA, Ye Y, et al. Antibody-drug conjugates designed to eradicate tumors with homogeneous and heterogeneous expression of the target antigen. Cancer Res 2006; 66 : 3214–21. [Google Scholar]
  20. Doronina SO, Toki BE, Torgov MY, et al. Development of potent monoclonal antibody auristatin conjugates for cancer therapy. Nat Biotechnol 2003; 21 : 778–84. [Google Scholar]
  21. Doronina SO, Mendelsohn BA, Bovee TD, et al. Enhanced activity of monomethylauristatin F through monoclonal antibody delivery : effect of linker technology on efficacy and toxicity. Bioconjug Chem 2006; 17 : 114–24. [Google Scholar]
  22. Ojima I. Guided molecular missiles for tumor-targeting chemotherapy : case studies using the second generation taxoids as warheads. Acc Chem Res 2008; 41 : 108–19. [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.